Ratings Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
1.05 ^USD	-1.87%		-7.89%	-27.59%

Apr. 12	Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement	CI
Mar. 12	Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
RIGEL PHARMACEUTICALS, INC.	-27.59%	188M	B-
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.29B	B+
ARGENX SE	+2.13%	22.18B	B
BIONTECH SE	-15.84%	21.2B	B+
GENMAB A/S	-9.21%	18.31B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.38B	A-
BEIGENE, LTD.	-14.65%	16.36B	B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.97B	C+
SAREPTA THERAPEUTICS, INC.	+31.35%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes